• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

硬皮病继发重度肺动脉高压的治疗：一种三联药物疗法。

Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.

作者信息

Catapano-Minotti Girolamo, Corsonello Andrea, Guadalupi Giovanni, Spani Rosalia, Antonelli-Incalzi Raffaele

机构信息

San Raffaele Foundation, Cittadella della Carita, Taranto, Italy.

出版信息

Intern Med. 2008;47(6):511-3. doi: 10.2169/internalmedicine.47.0565. Epub 2008 Mar 17.

DOI:10.2169/internalmedicine.47.0565
PMID:18344637
Abstract

We present a case of scleroderma complicated by severe pulmonary hypertension. The use of a three-drug (bosentan, iloprost, and sildenafil) approach contributed to significant improvement of both the clinical conditions and the pulmonary hemodynamics. Combining three pulmonary vasodilators with different mechanisms of action could benefit patients with severe pulmonary hypertension resistant to conventional therapy.

摘要

我们报告一例硬皮病合并严重肺动脉高压的病例。采用三种药物（波生坦、伊洛前列素和西地那非）联合治疗显著改善了临床状况和肺血流动力学。联合使用三种作用机制不同的肺血管扩张剂可能使对传统治疗耐药的严重肺动脉高压患者受益。

相似文献

1
Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.硬皮病继发重度肺动脉高压的治疗：一种三联药物疗法。
Intern Med. 2008;47(6):511-3. doi: 10.2169/internalmedicine.47.0565. Epub 2008 Mar 17.
2
[The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].[特发性肺动脉高压的治疗及其与系统性硬化症的关系]
Rev Med Interne. 2007 Dec;28 Suppl 4:S273-6. doi: 10.1016/j.revmed.2007.09.012. Epub 2007 Oct 8.
3
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.在其许可适应症范围内，依前列醇、伊洛前列素、波生坦、西他生坦和西地那非治疗肺动脉高压的临床和成本效益：系统评价和经济评估。
Health Technol Assess. 2009 Oct;13(49):1-320. doi: 10.3310/hta13490.
4
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.肺动脉高压的观察性试验：科学证据不足但临床价值高。
Eur Respir J. 2007 Mar;29(3):432-4. doi: 10.1183/09031936.00001607.
5
Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension.西地那非和伊洛前列素联合治疗患有肺动脉高压的早产儿。
Pediatr Pulmonol. 2011 Jun;46(6):617-20. doi: 10.1002/ppul.21415. Epub 2011 Mar 24.
6
[Bosentan and chronic thromboembolic pulmonary hypertension].[波生坦与慢性血栓栓塞性肺动脉高压]
Med Clin (Barc). 2007 Nov 3;129(16):639. doi: 10.1157/13111817.
7
Combination drug therapy in the management of pulmonary arterial hypertension.联合药物疗法在肺动脉高压管理中的应用
Prog Cardiovasc Nurs. 2005 Fall;20(4):177-82. doi: 10.1111/j.0889-7204.2005.04039.x.
8
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.在肺动脉高压患者中，西地那非联合波生坦单药治疗。
Eur Respir J. 2007 Mar;29(3):469-75. doi: 10.1183/09031936.00081706. Epub 2006 Nov 1.
9
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.波生坦作为一线单药治疗系统性硬皮病相关肺动脉高压的长期疗效，是否联合前列环素或西地那非。
Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.
10
"Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation.肺动脉高压的“达标治疗”以及体外膜肺氧合作为移植过渡手段的应用
Eur Respir Rev. 2011 Dec;20(122):297-300. doi: 10.1183/09059180.00005511.

引用本文的文献

1
Potential effect of Sildenafil beyond pulmonary hypertension in a patient with diffuse systemic sclerosis and cryoglobulinemic vasculitis.西地那非对一名弥漫性系统性硬化症合并冷球蛋白血症性血管炎患者除肺动脉高压之外的潜在影响。
Springerplus. 2014 Sep 26;3:559. doi: 10.1186/2193-1801-3-559. eCollection 2014.
2
Targeted therapy for systemic sclerosis: how close are we?系统性硬皮病的靶向治疗：我们离目标还有多远？
Nat Rev Rheumatol. 2010 May;6(5):269-78. doi: 10.1038/nrrheum.2010.48. Epub 2010 Apr 13.